AGL 6.45 Decreased By ▼ -0.05 (-0.77%)
ANL 9.50 Decreased By ▼ -0.20 (-2.06%)
AVN 74.95 Decreased By ▼ -0.88 (-1.16%)
BOP 5.35 Increased By ▲ 0.03 (0.56%)
CNERGY 4.80 Decreased By ▼ -0.05 (-1.03%)
EFERT 78.00 Increased By ▲ 0.51 (0.66%)
EPCL 54.15 Decreased By ▼ -1.06 (-1.92%)
FCCL 15.00 Decreased By ▼ -0.25 (-1.64%)
FFL 6.20 Decreased By ▼ -0.10 (-1.59%)
FLYNG 7.01 Increased By ▲ 0.16 (2.34%)
GGGL 10.05 Decreased By ▼ -0.12 (-1.18%)
GGL 15.94 Decreased By ▼ -0.37 (-2.27%)
GTECH 7.85 Increased By ▲ 0.41 (5.51%)
HUMNL 6.27 Decreased By ▼ -0.06 (-0.95%)
KEL 2.83 Decreased By ▼ -0.14 (-4.71%)
LOTCHEM 27.65 Decreased By ▼ -0.65 (-2.3%)
MLCF 27.00 Decreased By ▼ -0.56 (-2.03%)
OGDC 73.35 Decreased By ▼ -0.65 (-0.88%)
PAEL 15.30 Decreased By ▼ -0.29 (-1.86%)
PIBTL 5.15 Decreased By ▼ -0.10 (-1.9%)
PRL 16.10 Decreased By ▼ -0.48 (-2.9%)
SILK 1.04 Decreased By ▼ -0.02 (-1.89%)
TELE 10.45 Decreased By ▼ -0.20 (-1.88%)
TPL 7.69 Decreased By ▼ -0.19 (-2.41%)
TPLP 19.22 Decreased By ▼ -0.48 (-2.44%)
TREET 22.75 Decreased By ▼ -0.25 (-1.09%)
TRG 115.90 Decreased By ▼ -4.20 (-3.5%)
UNITY 21.80 Decreased By ▼ -0.34 (-1.54%)
WAVES 11.15 Decreased By ▼ -0.05 (-0.45%)
WTL 1.12 Decreased By ▼ -0.03 (-2.61%)
BR100 4,039 Decreased By -56.1 (-1.37%)
BR30 14,984 Decreased By -242.5 (-1.59%)
KSE100 40,620 Decreased By -307.7 (-0.75%)
KSE30 15,213 Decreased By -142.6 (-0.93%)
World

Pfizer to halt biosimilar output in China, sell assets to WuXi Biologics

  • The facilities are equipped with bioreactors and capable of filing vials and syringes, the Chinese firm said in a statement on the WeChat app.
Published March 17, 2021
Follow us

BEIJING: Pfizer Inc has decided to stop producing biosimilar products in China and sell a unit in the eastern city of Hangzhou to WuXi Biologics Inc, the US drugmaker said on Wednesday.

The pharmaceutical industry increasingly relies for its profits on costly biologic drugs, made from living organisms that are tougher and more expensive to make than conventional medicines with chemical ingredients.

"The site was planned to manufacture three biosimilars for the China market," the company said in a response to Reuters.

"Pfizer commercially and technically evaluated other products for the site but none reached the level of activity for the scale of the site."

Neither Pfizer nor WuXi disclosed the deal value, or the products to be made after the transaction closes, which is expected in the first half of this year. WuXi said the deal would allow it to address surging manufacturing demand for drug substances and drug products.

The facilities are equipped with bioreactors and capable of filing vials and syringes, the Chinese firm said in a statement on the WeChat app.

WuXi also makes vaccine substances for a COVID-19 shot developed by AstraZeneca PLC and the University of Oxford to supply them to Brazil, but did not have immediate comment on whether the plant would turn out such substances.

Comments

Comments are closed.